65 results about "Interstitial pneumonia" patented technology

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and / or multinucleated / giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.

This invention is directed to methods of preventing or treating diseases or conditions of the lungs associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. Particularly, this invention is directed to methods of treating pulmonary diseases such as asthma; chronic obstructive pulmonary disease; respiratory tract illness caused by respiratory syncytial virus; pulmonary arterial hypertension; acute respiratory distress syndrome and ventilator induced lung injury; cystic fibrosis; bronchiectasis; alpha-1-antitrypsin deficiency; rhinitis; rhinosinusitis; primary ciliary dyskinesia; pneumonia; bronchiolitis caused by agents other than respiratory syncytial virus; and interstitial lung disease including lymphangioleiomyomatosis; idiopathic pulmonary fibrosis; obliterative bronchiolitis or bronchiolitis obliterans organizing pneumonia due to lung transplantation or HSCT; nonspecific interstitial pneumonia; cryptogenic organizing pneumonia; acute interstitial pneumonia; respiratory bronchiolitis-associated interstitial lung disease; or pulmonary sarcoidosis. The method comprises administering to a subject an effective amount of a rho kinase inhibitor compound to treat the disease.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

The invention relates to compounds of formula (A) and formula (I):or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.). Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and / or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.

The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis / gliosis in the eye, schleroderma, and systemic sclerosis. The compounds of Formula (I) are also useful for treating subjects with both HCV and fibrosis in a mammal, particularly liver fibrosis, and subjects affirmatively diagnosed or at risk for both HCV and liver fibrosis.

The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis / gliosis in the eye, schleroderma, and systemic sclerosis. The compounds of Formula (I) are also useful for treating subjects with both HCV and fibrosis in a mammal, particularly liver fibrosis, and subjects affirmatively diagnosed or at risk for both HCV and liver fibrosis.

The invention discloses a traditional Chinese medicine formula for treating interstitial pneumonia. The formula is prepared from cordyceps sinensis, musk, pearl, borneol, poria cum radix pini, radix scutellariae, cortex mori radicis, trichosanthes kirilowii maxim, bulbus fritillariae cirrhosae, bulbus fritillariae thunbergii, pangolin scales, exocarpium citri rubrum, uncaria rhynchophylla and other raw medicinal materials. The traditional Chinese medicine formula has simple composition and natural sources, has good and stable effect on treatment of interstitial pneumonia, has no obvious toxic or side effect and complications, and has simple operation of preparation work.

The present invention provides a method for detecting idiopathic interstitial pneumonia, which comprises measuring the expression level of a periostin gene or the amount of a periostin protein in a biological sample. Thereby, a method for detecting idiopathic interstitial pneumonia using a marker is provided.

A traditional Chinese medicine for remedying the interstitial pneumonia belongs to the traditional Chinese medicine for remedying the pneumonia. The main prescription is 20 grams of heterophylly falsestarwort roots, 25 grams of milkvetch roots, 15 grams of tubers of dwarf lilyturf, 15 grams of radixes adenophorae, 10 grams of Szechwan fritillary bulbs, 10 grams of peach nuts, 12 grams of angelica roots, 10 grams of safflowers, 12 grams of danshen roots, 12 grams of earthworms, 9 grams of schisandra fruits, 10 grams of stemona roots and 12 grams of white swallowwort. The auxiliary prescriptions are that for with patient with serious pulmonary heat of the symptoms of red tongue, yellow fur, coughing with yellow thick phlegm etc., 10 grams of baical skullcap roots and 30 grams of heartleaf houttuynia herbs are added; for the patient with serious oppression in the chest, 10 grams snakegourd peels of and 10 grams of balloonflower roots are added. The compatibility of the traditional Chinese herbal medicines is simple; the medicines used in the medicine prescription are all natural herbal medicines which can be conveniently gotten and used; the manufacturing method is simple; the curative effect after being taken is good; the medicine price is cheap, and the medicine is especially fit for people who live at the remote small villages away from villages and towns to use. The treatment expense for the patient with the disease of the interstitial pneumonia is low, which solves the treatment problem which is caused by low family income, poor living and lack of local medical treatment condition.

As a compound having a potent oral activity and a long-lasting cysLT1 / cysLT2 receptor antagonistic activity, the compound of the formula (I):which exhibits potent antagonistic activity against the cysLT1 / cysLT2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and / or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.

The invention discloses application of an compound of an anti-human CD4 monoclonal antibody and an anti-human CD184 monoclonal antibody serving as markers, in particular relates to application of the anti-human CD4 monoclonal antibody and the anti-human CD184 monoclonal antibody serving as markers for diagnosing connective tissue disease correlated interstitial pneumonia, application of the anti-human CD4 monoclonal antibody and the anti-human CD184 monoclonal antibody to preparation of a reagent or kit for diagnosing the connective tissue disease correlated interstitial pneumonia, or application of the anti-human CD4 monoclonal antibody and the anti-human CD184 monoclonal antibody to preparation of a reagent or kit for judging the severity degree, regression or prognosis of the connective tissue disease correlated interstitial pneumonia. The invention further provides a corresponding kit.